The Pharmacy and Poisons Board (PPB), in partnership with the National Vaccines and Immunization Program (NVIP) and CIHEB-Kenya, has released findings from the 2023 COVID-19 Cohort Event Monitoring Study.
The study, presented by Dr. Ahmed Mohammed, Director of Health Products and Technologies at PPB, confirms that COVID-19 vaccines administered in Kenya are safe.
Most reported side effects, such as headaches, injection site pain, fever, and dizziness, were mild to moderate and typically resolved within 48 hours. Factors like age, vaccine type, and pre-existing conditions played a role in the occurrence of side effects.
Kenya’s participation in the AU-3S program, alongside countries like Ghana, Nigeria, South Africa, and Ethiopia, showed no new safety concerns, further supporting global vaccine safety data.
